{
    "root": "7632f6be-f964-4116-93aa-c070d042749b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Dexmedetomidine",
    "value": "20250311",
    "ingredients": [
        {
            "name": "DEXMEDETOMIDINE HYDROCHLORIDE",
            "code": "1018WH7F9I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31472"
        },
        {
            "name": "NATURAL LATEX RUBBER",
            "code": "2LQ0UUW8IN"
        }
    ],
    "indications": {
        "text": "dexmedetomidine injection dexmedetomidine 5 % dextrose injection alpha 2 adrenergic receptor agonist indicated : \u2022 sedation initially intubated mechanically ventilated adult patients treatment intensive care setting . administer dexmedetomidine injection dexmedetomidine 5 % dextrose injection continuous infusion exceed 24 hours . ( 1.1 ) \u2022 sedation non-intubated adult patients prior and/or surgical procedures . ( 1.2 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 individualize titrate dosing desired effect . ( 2.1 ) \u2022 duration exceed 24 hours . ( 2.1 ) \u2022 administer intravenously using controlled infusion device . ( 2.1 ) \u2022 dexmedetomidine injection must diluted prior . ( 2.1 ) \u2022 dexmedetomidine injection 5 % dextrose 200 mcg/50 ml 400 mcg/100 ml single-dose bags , require dilution prior . ( 2.1 ) \u2022 administered health care providers skilled management patients intensive care operating room setting . ( 2.1 ) \u2022 continuously monitor blood pressure , heart rate , oxygen levels clinically appropriate discontinuation . ( 2.1 ) \u2022 necessary discontinue dexmedetomidine injection dexmedetomidine 5 % dextrose injection prior extubation . \u2022 adult intensive care unit sedation : \u2022 initiate one mcg/kg 10 minutes , followed maintenance infusion 0.2 0.7 mcg/kg/ hour . ( 2.2 ) \u2022 adult procedural sedation : initiate one mcg/kg 10 minutes , followed maintenance infusion initiated 0.6 mcg/kg/ hour titrated achieve desired effect doses ranging 0.2 1 mcg/kg/ hour . ( 2.2 ) \u2022 alternative doses : recommended patients 65 years age awake fiberoptic intubation patients . ( 2.2 ) \u2022 full prescribing information recommended , reconstitution , dilution , instructions . ( 2.2 , 2.3 , 2.4 , 2.5 , 2.6 , 2.7 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "none .",
    "indications_original": "Dexmedetomidine Injection and Dexmedetomidine in 5% Dextrose Injection is a alpha 2 adrenergic receptor agonist indicated for: \u2022 Sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Administer Dexmedetomidine Injection and Dexmedetomidine in 5% Dextrose Injection by continuous infusion not to exceed 24 hours. (1.1) \u2022 Sedation of non-intubated adult patients prior to and/or during surgical and other procedures. (1.2)",
    "contraindications_original": "\u2022 Individualize and titrate dosing to desired clinical effect. (2.1) \u2022 Administration duration should not exceed 24 hours. (2.1) \u2022 Administer intravenously using a controlled infusion device. (2.1) \u2022 Dexmedetomidine Injection must be diluted prior to administration. (2.1) \u2022 Dexmedetomidine Injection in 5% Dextrose 200 mcg/50 mL and 400 mcg/100 mL single-dose bags, do not require dilution prior to administration. (2.1) \u2022 To be administered only by health care providers skilled in management of patients in the intensive care or operating room setting. (2.1) \u2022 Continuously monitor blood pressure, heart rate, and oxygen levels during administration and as clinically appropriate after discontinuation. (2.1) \u2022 It is not necessary to discontinue Dexmedetomidine Injection and Dexmedetomidine in 5% Dextrose Injection prior to extubation. \u2022 For Adult Intensive Care Unit Sedation : \u2022 Initiate at one mcg/kg over 10 minutes , followed by a maintenance infusion of 0.2 to 0.7 mcg/kg/ hour . (2.2) \u2022 For Adult Procedural Sedation : Initiate at one mcg/kg over 10 minutes , followed by a maintenance infusion initiated at 0.6 mcg/kg/ hour and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/ hour . (2.2) \u2022 Alternative Doses : Recommended for patients over 65 years of age and awake fiberoptic intubation patients. (2.2) \u2022 See full prescribing information for recommended dosage, reconstitution, dilution, and administration instructions. (2.2, 2.3, 2.4 ,2.5, 2.6, 2.7)",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "Dexmedetomidine",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4466"
        }
    ]
}